Visionflex (ASX:VFX) turns cash flow positive as RFDS anchors a new product category

A$0.7m of Q4 operating cash inflow lands as unattended virtual care opens unstaffed clinic markets

Visionflex Group (ASX:VFX) has delivered the result its shareholders have been waiting on for the better part of two years. The Q4 FY26 quarterly shows A$0.7 million of operating cash inflow for the quarter and positive operating cash flow across the entire second half of FY26. For a small-cap virtual care hardware and software play that was still burning through cash a year ago, that is a genuine inflection point.

The full-year operating cash outflow narrowed to A$1.2 million, a A$1.9 million improvement on the prior corresponding period. Operating and admin payments dropped 18% for the year, largely because of the February workforce restructure that reset the cost base without denting the sales function.

The revenue line, though, tells a messier story. Q4 unaudited revenue of A$1.5 million was down 23% on the pcp, and full-year revenue of A$4.2 million was down 10%. Management pins the shortfall on customers deferring hardware deliveries into Q1 FY27, and the contracts genuinely appear to be signed and committed. But investors will want the Q1 update to confirm that revenue actually lands where management says it will.

The cost reset did the heavy lifting, not the top line

This is fundamentally a cost-out story, not a revenue growth story. Cash receipts grew 8% to A$4.9 million for the year, which is fine but hardly transformational. The move to cash-flow positive came from stripping A$1.5 million out of operating and admin payments.

That matters because it changes the required trajectory. Visionflex no longer needs to double revenue to survive. It needs to hold its cost base and grow the top line modestly. The A$1.6 million cash balance plus A$1.05 million of undrawn facilities gives the business enough runway to actually execute on that plan without another dilutive raise hanging over the stock.

The skeptical read is that a A$4.2 million revenue business that took years to reach breakeven still has to prove it can grow. The workforce restructure was a one-off. Future cost gains will be harder to find.

Unattended access is the interesting new product line

Buried under the cash flow headlines is a product launch that could matter more than the quarterly numbers. Visionflex has launched an unattended access capability, meaning a clinician can now run a full remote consultation and operate the examination devices with no trained operator at the patient end.

This opens up settings that were previously off-limits. Unstaffed clinics, mining and resources sites, corporate health and after-hours aged care. RFDS SA/NT signed as the first customer and begins network deployment in Q1 FY27, part of a A$0.3 million contract that also covers subscription upgrades across 12 existing facilities and expansion to eight more.

We think this is the more strategically important development in the quarterly. Diagnostic-grade virtual care without a bedside operator is a materially larger addressable market than the staffed model that dominated the platform’s history.

The ARR transition risk investors need to watch

Annual Recurring Revenue sits at A$1.95 million, up just 3% on the pcp. Management has been transparent about a genuine risk sitting inside that number. A portion of the aged care subscription base was originally deployed under Primary Health Network funded programs, and those facilities have to transition to customer-funded subscriptions during FY27.

Retention will vary by facility depending on how heavily the platform is being used. Management says the objective is to offset any churn with new subscription contracts, but this is the single biggest operational risk in FY27. NSW Health at A$0.8 million and the growing list of aged care rollouts help, though converting hardware wins into sticky recurring revenue is still the tougher part of the model.

The Investors Takeaway for Visionflex Group

The FY26 result cleans up the balance sheet story and buys the company time. The FY27 question is whether Josh Mundey can convert the enterprise pipeline, land meaningful deployments of the unattended access product with customers beyond RFDS, and offset the churn risk in the aged care subscription base before it shows up in the ARR number.

The setup is more attractive than it has been in years. A cash flow positive small-cap on a A$4.2 million revenue base with a genuinely differentiated new product and roughly A$2.65 million of total available liquidity has meaningful optionality. Execution over the next two quarters is what turns that optionality into a re-rating. Investors looking for more small-cap health tech coverage can browse our archive at stocksdownunder.